Wall Street brokerages expect MediWound Ltd. (NASDAQ:MDWD) to announce earnings of ($0.19) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for MediWound’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.20). MediWound posted earnings per share of ($0.26) during the same quarter last year, which would suggest a positive year-over-year growth rate of 26.9%. The firm is expected to issue its next earnings report on Monday, November 13th.

On average, analysts expect that MediWound will report full year earnings of ($0.76) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.70). For the next financial year, analysts anticipate that the firm will report earnings of ($0.65) per share, with EPS estimates ranging from ($0.85) to ($0.48). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow MediWound.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. MediWound’s revenue for the quarter was up 93.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.34) EPS.

Several brokerages have weighed in on MDWD. Zacks Investment Research cut MediWound from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $10.00 target price on MediWound and gave the stock a “buy” rating in a report on Tuesday, October 17th. Jefferies Group LLC set a $10.00 target price on MediWound and gave the stock a “buy” rating in a report on Friday, August 25th. ValuEngine upgraded MediWound from a “strong sell” rating to a “sell” rating in a report on Friday. Finally, Cowen and Company began coverage on MediWound in a report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $9.15.

COPYRIGHT VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/23/0-19-earnings-per-share-expected-for-mediwound-ltd-mdwd-this-quarter-2.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its position in shares of MediWound by 19.7% in the 1st quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after acquiring an additional 8,745 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of MediWound by 1.7% in the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 1,300 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of MediWound by 20.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after acquiring an additional 342,165 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of MediWound by 11.0% in the 1st quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after acquiring an additional 213,745 shares in the last quarter. 19.55% of the stock is owned by hedge funds and other institutional investors.

MediWound (MDWD) opened at 5.00 on Monday. MediWound has a 12-month low of $4.25 and a 12-month high of $8.25. The company’s market cap is $109.77 million. The firm has a 50-day moving average price of $5.37 and a 200-day moving average price of $6.33.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on MediWound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.